Print this page    •   Back to Web version of article

Comparing Protease Combinations

May 1996

Reported maximum average reductions in plasma
RNA with selected protease inhibitor combinations
(in treament naive/experienced* individuals)
SQV.6 logS. Vella
SQV(new formulation)1.5 logRoche
RTV1.2-1.9 logAbbott
IDV1.2-2.0 logMerck
NFV1.5 logMarkowitz
SQV+AZT1.0 logS. Vella
SQV+ddC.6 logRoche NV*
SQV+AZT+ddC.8 logACTG 229*
RTV+AZT1.2 logAbbott
RTV+AZT+ddC2.0-2.5 logLeibowich
IDV+AZT1.4-1.5 logMerck
IDV+AZT+ddl2.9 logMerck
IDV+AZT3TC>2.0 logMerck 035*
NFV+d4T2.4-2.6 logChapman

This article was provided by Treatment Action Group. It is a part of the publication TAGline. You can find this article online by typing this address into your Web browser:

General Disclaimer: is designed for educational purposes only and is not engaged in rendering medical advice or professional services. The information provided through should not be used for diagnosing or treating a health problem or a disease. It is not a substitute for professional care. If you have or suspect you may have a health problem, consult your health care provider.